Financial Performance - The company's revenue for the six months ended June 30, 2021, was RMB 18,310,000, an increase of 12.2% compared to RMB 16,311,000 for the same period in 2020[8]. - The cost of sales and services for the same period was RMB 7,732,000, up from RMB 7,076,000, reflecting a 9.3% increase[8]. - The net profit attributable to the owners of the company was RMB (312,000), a decrease from RMB 2,997,000 in the previous year, indicating a significant decline in profitability[10]. - The total revenue for the funeral services and cremation services segment increased to RMB 35,521,000 in 2021 from RMB 27,535,000 in 2020, representing a growth of approximately 29%[33]. - The total profit for the reportable segments reached RMB 8,697,000 for the six months ended June 30, 2021, compared to RMB 3,193,000 for the same period in 2020, indicating an increase of approximately 172%[42]. - The company reported a total revenue of RMB 37,271,000 for the six months ended June 30, 2021, up from RMB 28,985,000 in the same period of 2020, reflecting a growth of about 29%[39]. - The company reported a pre-tax consolidated profit of RMB 4,711,000 for the six months ended June 30, 2021, compared to RMB 1,452,000 for the same period in 2020, an increase of approximately 224%[42]. - The income tax expense for the six months ended June 30, 2021, was RMB 2,896,000, significantly higher than RMB 940,000 in the same period of 2020[79]. Assets and Liabilities - The total assets as of June 30, 2021, amounted to RMB 153,519,000, compared to RMB 146,882,000 at the end of 2020, showing a growth of 4.4%[12]. - Cash and cash equivalents at the end of the reporting period were RMB 125,616,000, slightly up from RMB 123,674,000 at the beginning of the year[18]. - Trade receivables increased to RMB 1,291 thousand as of June 30, 2021, from RMB 996 thousand as of December 31, 2020, representing a growth of 29.5%[96]. - The net amount of trade receivables after expected credit loss provisions was RMB 914 thousand, up from RMB 619 thousand, indicating a 47.7% increase[96]. - The group’s financial liabilities measured at amortized cost decreased to RMB 14,847 thousand from RMB 16,876 thousand, a decline of 12.1%[103]. - The group’s capital commitments to joint ventures and associates were approximately RMB 8,700,000 as of June 30, 2021, up from RMB 6,500,000 as of December 31, 2020, indicating a growth of about 33.85%[110]. Expenses - Administrative expenses increased to RMB 8,149,000 from RMB 4,688,000, reflecting a rise of 73.5%[8]. - The sales cost for the period was approximately RMB 15,570,000, an increase of about 16.5% from RMB 13,361,000 in the previous period[132]. - Administrative expenses increased by approximately 26.9% to about RMB 13,764,000, accounting for 36.9% of revenue[134]. Cash Flow - The company reported a net cash inflow from operating activities of RMB 731,000, a significant decrease from RMB 9,156,000 in the same period last year[18]. - The group maintained a strong cash position with approximately RMB 125,616,000 in cash and bank balances as of June 30, 2021[136]. Market and Strategic Focus - The company plans to focus on market expansion and new product development to enhance future growth prospects[8]. - The group reported a significant focus on investment holding, primarily in funeral and related services in China, Taiwan, and Hong Kong, as well as cemetery sales in Vietnam and high-end biotech equipment sales in Hong Kong[20]. - The group plans to adhere to a diversified development strategy, allocating more resources to support the growth of its biotechnology business[149]. - The group aims to expand its investment business scale through equity and securities investment operations[149]. Compliance and Reporting - The unaudited interim financial statements were prepared in accordance with the Hong Kong Financial Reporting Standards, with no significant impact from the newly adopted standards during the reporting period[28]. - The financial statements are presented in Renminbi, with amounts rounded to the nearest thousand, indicating a structured approach to financial reporting[26]. - The management's application of accounting policies remains consistent with those used in the previous financial year, ensuring stability in financial reporting[24]. - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the period and confirmed compliance with applicable accounting standards[175]. Employee and Management Compensation - The total remuneration for key management personnel for the six months ended June 30, 2021, was RMB 1,892,000, an increase of 25.14% from RMB 1,512,000 in the same period of 2020[111]. - The total remuneration for close relatives of key management personnel was RMB 128,000 for the six months ended June 30, 2021, compared to RMB 116,000 in the same period of 2020, reflecting a growth of approximately 10.34%[112]. Shareholder Information - As of June 30, 2021, Hong Kong Gaoqi Biotechnology Co., Ltd. held 220,475,000 shares, representing approximately 29.69% of the company's issued share capital[153]. - The company has adopted a new share option plan effective from April 22, 2021, which will remain valid for ten years, allowing for the issuance of up to 10% of the total issued shares as of the adoption date[161]. - The maximum number of shares that can be issued under the share option plan is 74,250,000 shares, representing 10% of the total issued shares as of the mid-term performance report date[164]. - No share options have been granted under the share option plan since its adoption date[165]. - The company did not purchase, sell, or redeem any of its listed securities during the reporting period[167].

Financial Performance - The company reported revenue of RMB 18,961,000 for the three months ended March 31, 2021, an increase of 49.7% compared to RMB 12,674,000 for the same period in 2020[8]. - Gross profit for the same period was RMB 11,123,000, resulting in a gross margin of approximately 58.7%, compared to RMB 6,389,000 and a gross margin of 50.4% in the previous year[8]. - Operating profit reached RMB 4,620,000, a significant improvement from an operating loss of RMB 1,326,000 in the prior year[8]. - The company achieved a profit before tax of RMB 3,975,000, compared to a loss before tax of RMB 2,064,000 in the same quarter of 2020[8]. - Net profit attributable to owners of the company was RMB 2,657,000, compared to a loss of RMB 2,109,000 in the previous year[8]. - The basic and diluted earnings per share for the quarter were RMB 0.36, compared to a loss per share of RMB 0.28 in the same quarter of 2020[8]. - The company reported total comprehensive income of RMB 3,787,000 for the quarter, compared to a total comprehensive loss of RMB 154,000 in the previous year[8]. - Total revenue for the period was approximately RMB 18,961,000, an increase of about 49.6% from RMB 12,674,000 in the previous period[41]. - Basic earnings per share for the period ended March 31, 2021, was RMB 0.36, compared to a loss of RMB 0.28 in the same period last year[32]. - The company reported a profit attributable to owners of RMB 2,657,000 for the period, compared to a loss of RMB 2,109,000 in the previous period[41]. Revenue Sources - The group's revenue from funeral services and cremation services for the three months ended March 31, 2021, was RMB 18,210,000, an increase of 51% compared to RMB 12,078,000 for the same period in 2020[22]. - Revenue from funeral arrangements and related consulting services was RMB 632,000, up 34% from RMB 470,000 in the previous year[22]. - Revenue from the Chinese market was approximately RMB 18,210,000, representing a significant increase of about 50.8% compared to RMB 12,078,000 in the previous period[37]. - Revenue from Taiwan increased by approximately 86.8% to RMB 396,000, while revenue from Hong Kong decreased by about 8.5% to RMB 236,000[39]. - Total revenue from external customers for the three months ended March 31, 2021, was RMB 18,961,000, compared to RMB 12,674,000 for the same period in 2020, reflecting a growth of 49%[25]. Operational Strategy - The company continues to focus on expanding its services in the funeral and related services sector in China, Taiwan, and Hong Kong[14]. - The company is also involved in the sale of cemetery plots and tombstones in Vietnam, as well as providing high-end biotechnology instruments and electronic products in Hong Kong and China[14]. - The company is committed to enhancing its operational efficiency and exploring new market opportunities to drive future growth[14]. - The company plans to allocate more resources to develop the emerging biotechnology industry while consolidating its traditional funeral service business[49]. - The biotechnology sector will integrate with new technologies such as artificial intelligence, big data, and the internet, focusing on innovations like medical robots and desktop electron microscopes[49]. - The company aims to enhance external cooperation through business licensing, equity investments, and mergers and acquisitions to improve operational conditions and optimize business structure[49]. - Various incentive measures will be implemented to attract and retain top talent and management personnel, contributing to the company's development[49]. Tax and Dividend Information - The group reported no tax provisions for Hong Kong profits tax during the period, as there were no taxable profits generated in Hong Kong[26]. - The group’s subsidiary in Chongqing, which benefits from a preferential tax rate of 15%, continued to apply this rate during the reporting period[28]. - The company did not recommend any dividend payments for the period, consistent with the previous period[31]. Challenges and Management - The company faced delays in financial reporting due to COVID-19 travel restrictions, impacting the audit of the financial statements for the year ended December 31, 2020[62]. - The company plans to continue monitoring the impact of COVID-19 on its financial performance and operations[44]. - The company maintains a prudent financial management strategy and aims to keep an appropriate level of liquidity to seize acquisition opportunities[46]. - The company’s operations in China have shown resilience against the impacts of COVID-19, with no significant adverse effects on its funeral and cremation services[47]. - The company established an audit committee to review and monitor financial reporting procedures and internal control systems[64]. - The audit committee consists of three independent non-executive directors, ensuring compliance with GEM listing rules[64]. Shareholder Information - The company reported a significant shareholder, Hong Kong Gaoqi Biotechnology Co., Ltd., holding 29.69% of the shares, equating to 220,475,000 shares[53]. - There were no significant contracts involving directors with a direct or indirect interest in the company's business during the reporting period[56]. - The company has not engaged in any arrangements that would allow directors or senior executives to acquire securities of the company or its affiliates during the reporting period[57].

8 於開發群島註冊成立的有限公司 股份代號:8296 JLLEST SINO LIFE GROUP LIMITED 中 國 生 命 集 團 有 限 公 司 2020 第三季度報告 H2( 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料；本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所 ...

Financial Performance - Revenue for the six months ended June 30, 2020, was RMB 28,985,000, a decrease of 8.6% compared to RMB 31,705,000 for the same period in 2019[5] - Gross profit for the six months ended June 30, 2020, was RMB 15,624,000, representing a gross margin of 54.0%[5] - Operating profit for the six months ended June 30, 2020, was RMB 2,800,000, compared to RMB 1,429,000 for the same period in 2019[5] - Profit before tax for the six months ended June 30, 2020, was RMB 1,452,000, compared to RMB 201,000 for the same period in 2019[5] - Net profit for the six months ended June 30, 2020, was RMB 512,000, compared to a loss of RMB 372,000 for the same period in 2019[5] - Total comprehensive income for the six months ended June 30, 2020, was RMB 2,933,000, compared to RMB 622,000 for the same period in 2019[5] - Basic and diluted earnings per share for the six months ended June 30, 2020, were RMB 0.12, compared to RMB 0.03 for the same period in 2019[7] - The group reported a profit attributable to owners of RMB 2,997,000 for the three months ended June 30, 2020, compared to a loss of RMB (1,307,000) for the same period in 2019[78] - The company reported a profit attributable to shareholders of approximately RMB 888,000, compared to RMB 242,000 in the previous period, with earnings per share of RMB 0.12, up from RMB 0.03[128] Revenue Breakdown - Revenue from funeral services and cremation services for the six months ended June 30, 2020, was RMB 27,535,000, an increase of 6.9% from RMB 25,746,000 in the same period of 2019[33] - Revenue from funeral arrangement and related consultation services decreased significantly to RMB 1,119,000, down 79.7% from RMB 5,483,000 in the previous year[33] - Total revenue for the group during the period was RMB 28,985,000, a decrease of 9.1% compared to RMB 31,705,000 in the same period of 2019[33] - Revenue from the Chinese market was approximately RMB 27,606,000, a decrease of about 7.9% compared to the previous period's RMB 29,958,000[119] - Revenue from Taiwan was approximately RMB 798,000, a decrease of about 39.0% from RMB 1,308,000 in the previous period[122] - Revenue from Hong Kong increased by approximately 21.6% to RMB 321,000, compared to RMB 264,000 in the previous period[124] - Revenue from Vietnam increased by approximately 48.6% to RMB 260,000, compared to RMB 175,000 in the previous period[125] - The funeral, cremation, and cemetery services in China contributed approximately RMB 27,535,000, down from RMB 29,657,000 in the previous period, reflecting a decrease of about 7.2%[121] Cash Flow and Assets - For the six months ended June 30, 2020, the net cash generated from operating activities was RMB 9,156 thousand, compared to a net cash used of RMB 2,565 thousand in the same period of 2019[14] - The total cash and cash equivalents increased by RMB 5,277 thousand, reaching RMB 129,024 thousand as of June 30, 2020, compared to RMB 115,764 thousand at the end of June 2019[14] - Total assets as of June 30, 2020, were RMB 224,256,000, an increase from RMB 216,588,000 as of December 31, 2019[10] - Total liabilities as of June 30, 2020, were RMB 103,235,000, compared to RMB 99,901,000 as of December 31, 2019[10] - Net assets attributable to the owners of the company as of June 30, 2020, were RMB 120,582,000, an increase from RMB 117,649,000 as of December 31, 2019[10] - As of June 30, 2020, the group maintained a cash and bank balance of approximately RMB 129,024,000, an increase from RMB 119,216,000 as of December 31, 2019[129] Expenses and Costs - Employee costs, including director remuneration, totaled RMB 9,640,000 for the six months ended June 30, 2020, slightly up from RMB 9,583,000 in the previous year[66] - The financing costs for the six months ended June 30, 2020, were RMB 1,348,000, compared to RMB 1,228,000 in 2019, representing an increase of approximately 9.8%[66] - Selling expenses decreased by approximately 44.9% to about RMB 3,107,000 due to reduced sales activities following the outbreak of Covid-19[126] - Administrative expenses increased by approximately 14.3% to about RMB 10,844,000, representing 37.4% of revenue, compared to 29.9% in the previous period[126] - The cost of sales decreased to approximately RMB 13,361,000, down about 14.7% from RMB 15,658,000 in the previous period, attributed to reduced revenue across all business segments[126] Corporate Governance and Compliance - The financial statements are prepared in accordance with the applicable disclosure requirements of the GEM Listing Rules and comply with Hong Kong Financial Reporting Standards[18] - The financial statements have not been audited but have been reviewed by the company's audit committee[21] - The audit committee, composed of three independent non-executive directors, reviewed the unaudited consolidated financial statements for the period and confirmed compliance with applicable accounting standards[175] - The company emphasized the importance of high-quality governance and transparency to its shareholders[171] - The company has adopted a code of conduct for securities transactions by directors, ensuring compliance with strict trading standards[174] Impact of COVID-19 - The group has decided to suspend the elderly care services segment, which will no longer be reported separately and is classified as "unallocated"[34] - The group recorded approximately RMB 71,000 in revenue from the sale of stem cells and immune cells, a significant decrease from RMB 301,000 in the previous period[121] - The company faced challenges in financial reporting due to the impact of the COVID-19 pandemic on its operations in Taiwan and Vietnam[177] - The group will continue to monitor the impact of Covid-19 on its financial condition and operational performance while exploring opportunities for investment and mergers to optimize its business structure[140] Shareholder Information - Major shareholder Hong Kong Gaoqi holds 220,475,000 shares, representing 29.69% of the company's issued share capital[143] - The company has not disclosed any other individuals holding 5% or more of the shares as of June 30, 2020[145] - No significant contracts were reported where directors had a substantial interest during the period[146] Stock Options and Management - The stock option plan allows for a maximum of 74,250,000 shares to be issued, equivalent to 10% of the total shares issued as of the mid-term report date[153] - The stock option plan was approved for a duration of ten years, expiring on August 23, 2019, with no further options to be granted[151] - The company has not entered into any management contracts for significant parts of its business during the period[148] - The company reported a total of 48,232,000 stock options granted, with none exercised or canceled during the period[168] Future Outlook - The company plans to diversify its development strategy by actively engaging in the cell industry and enhancing cooperation with foreign biotechnology companies to improve operational performance[138] - The group is currently evaluating the impact of new accounting standards and amendments, with preliminary results indicating no significant impact on financial performance and position[31]

Business Performance - The Group recorded an increase in its funeral services business in the PRC compared to the prior year, benefiting from ongoing population aging and growth in purchasing power [18] - The sales of stem cell and immunocytes in the PRC contributed approximately RMB1,591,000 to this year's revenue [20] - The sales of advanced biotechnical equipment business in Hong Kong contributed approximately RMB3,263,000 during the year [20] - The Group recorded an increase in its funeral services business in the PRC, benefiting from rising consumption and ongoing population aging, compared to the prior year [40] - Revenue from stem cell and immunocyte sales in the PRC contributed approximately RMB 1,591,000 for the year [23] - Revenue from advanced biotechnical equipment sales in Hong Kong contributed approximately RMB 3,263,000 for the year [23] - The Group's total revenue for the year was approximately RMB66,610,000, representing an increase of approximately 6.3% compared to the prior year (RMB62,667,000) [61] - Revenue from the funeral business in mainland China increased slightly by approximately 1.9% to approximately RMB59,868,000 compared to the prior year [45] - Revenue from Taiwan decreased by 14.1% during the year, reflecting challenges in the market [51] - The Group recorded revenue of approximately RMB4,063,000 from Hong Kong, representing a fourfold increase compared to the prior year [52] - The Group's operation in Vietnam generated revenue of approximately RMB421,000, showing stability compared to the prior year (RMB335,000) [58] - The Group's elderly care services are also part of its revenue generation strategy, alongside funeral services and biotechnology sales [59] - The Group's revenue for the Year was approximately RMB66,610,000, representing an increase of about 6.3% compared to the prior year (RMB62,667,000) due to the new business segments in stem cell and immunocyte sales as well as advanced life science equipment sales [65] Strategic Development - The Company disposed of 40% of its interests in Bau Shan Life Science Technology Co., Ltd in April 2019 to focus on the biological technology industry development [19] - The Group's diverse development strategy in the cells industry has achieved substantial progress, including the sales of stem cell and immunocytes [20] - The Group's strategy aims to capitalize on the booming biological technology business, which is expected to enhance future performance [19] - The Company is actively positioning itself in the biotech industry, particularly in the cells sector, to leverage market opportunities [20] - The Group established a joint venture for cell cultivation research and development, owning 30% of the equity interests, marking a strategic move into the upstream of the cell industrial chain [25] - The Group plans to continue developing its cell business while consolidating new technologies and exploring quality projects for sustainable growth [35] - The Group aims to consolidate new technologies and research talents through collaborative investments, mergers, and restructuring [104] - The strategy includes exploring other promising projects to enhance the core cell industry and optimize business structure [104] Financial Performance - Cost of sales for the Year was approximately RMB34,568,000, slightly down from RMB34,778,000 in the prior year, with a decrease of approximately RMB3,936,000 attributed to the decline in the funeral services segment, offset by an increase of approximately RMB3,726,000 from the new stem cell and immunocyte sales [64] - Gross profit for the Year was approximately RMB32,042,000, with a gross profit margin increase to approximately 48.1% from 44.5% in the prior year, mainly due to effective cost control in the funeral services segment and higher margins from the new stem cell and immunocyte business [68] - Selling expenses increased by approximately 28.8% to approximately RMB7,169,000, accounting for about 10.8% of revenue, primarily due to the commencement of the stem cell and immunocyte sales [68] - Administrative expenses were approximately RMB28,273,000, representing about 42.4% of revenue, which remained relatively stable compared to the prior year [68] - The loss attributable to the owners of the Company for the Year was approximately RMB3,804,000, compared to a loss of approximately RMB8,352,000 in the Prior Year, resulting in a loss per share of approximately RMB0.51 cents (Prior Year: RMB1.12 cents) [72] - The Group's gross profit margin for funeral services was 50.1%, while the gross profit margin for stem cells and immunocytes business was 64.7% [61] Risk Management - The Group faces risks including economic slowdown, increased market competition, and reliance on skilled employees [81] - Financial risks include market risk, credit risk, and liquidity risk, as detailed in the consolidated financial statements [81] - The Group has established procedures for identifying, assessing, and managing significant risks [197] - Risk assessment involves evaluating identified risks based on management-established criteria and considering their potential impact and likelihood [197] - The Group prioritizes risks based on assessment results and determines risk management strategies and internal control procedures [197] - Continuous monitoring of risks is conducted, with regular reporting to management and the board on risk monitoring outcomes [197] - The Board is responsible for overseeing the risk management and internal control systems, ensuring they are effective [200] Corporate Governance - The Group emphasizes the importance of corporate governance and compliance with the Code on Corporate Governance Practices [108] - The Company has adopted a code of conduct for Directors' securities transactions, ensuring compliance with GEM Listing Rules [110] - The Board held a total of 9 meetings during the year, with attendance rates for executive directors ranging from 5/9 to 9/9 [123] - The roles of Chairman and CEO are held separately by Mr. Xu Jianchun and Mr. Liu Tien-Tsai, ensuring a clear division of responsibilities [128] - The Board complies with GEM Listing Rules, maintaining at least 3 independent non-executive Directors, representing at least one-third of the Board [129] - The Company has established an Audit Committee consisting of three independent non-executive Directors, complying with GEM Listing Rules 5.28 to 5.33 [138] - The Audit Committee reviewed the quarterly reports, half-yearly report, and annual report, focusing on compliance with accounting standards and GEM Listing Rules [142] - The Company has a Remuneration Committee composed of three independent non-executive Directors, which advises the Board on remuneration packages [143] - The Company has established a Board Diversity Policy, which is reviewed and considered regularly [154] - The Company adopted a Board Nomination Policy to ensure that Directors possess relevant background, experience, and knowledge critical to the Group's business [158] Employee Relations - The Group maintains good relationships with employees, customers, and suppliers, with no significant disputes reported during the year [90] - The Group employed approximately 188 employees as of 31 December 2019, an increase from 169 employees in the Prior Year [78] - All Directors participated in continuous professional development, ensuring their contributions to the Board remain informed and relevant [133] Environmental and Social Responsibility - The Group emphasizes environmental conservation through green office practices and encourages electronic record-keeping to reduce paper consumption [82] - There were no material breaches of laws and regulations affecting the Group's operations during the year [87]

Financial Performance - The company reported a revenue of RMB 12,674,000 for the three months ended March 31, 2020, a decrease of 26.5% compared to RMB 17,275,000 for the same period in 2019[5]. - Gross profit for the same period was RMB 6,389,000, down from RMB 9,395,000 in the previous year, reflecting a gross margin decline[5]. - The company incurred a loss attributable to owners of RMB 2,109,000 for the quarter, compared to a profit of RMB 1,645,000 in the prior year[5]. - Operating loss for the quarter was RMB 1,326,000, a significant decline from an operating profit of RMB 2,109,000 in the same quarter of 2019[5]. - The total comprehensive income for the period was a loss of RMB 154,000, compared to a total comprehensive income of RMB 3,314,000 in the previous year[5]. - Basic and diluted loss per share was RMB 0.28, compared to earnings of RMB 0.22 per share in the same period last year[5]. - The company reported financing costs of RMB 738,000 for the quarter, which is an increase from RMB 70,000 in the previous year[5]. - The company’s administrative expenses were RMB 6,156,000, up from RMB 5,056,000 in the prior year, indicating increased operational costs[5]. - Other income for the quarter was RMB 416,000, a decrease from RMB 467,000 in the same period of 2019[5]. Revenue Breakdown - Revenue from funeral services and cremation services was RMB 12,078,000, down 26.5% from RMB 16,346,000 in the previous year[18]. - Revenue from the Chinese market accounted for 95.3% of total revenue, slightly down from 95.5% in the previous year[29]. - Revenue from Taiwan was RMB 212,000, representing 1.7% of total revenue, down from 3.0% in the previous year[29]. - Revenue from the Chinese market was approximately RMB 12,078,000, a decrease of about 26.8% compared to the previous period's RMB 16,490,000[30]. - The segment providing funeral, cremation, and cemetery services in China contributed approximately RMB 12,078,000, down from RMB 16,344,000, while sales of stem cells and immune cells recorded zero revenue, down from RMB 146,000[30]. - Revenue from Taiwan was approximately RMB 212,000, a decrease of about 59.6% from RMB 525,000 in the previous period, while revenue from Hong Kong increased by approximately 101.6% to RMB 258,000 from RMB 128,000[33][35]. - The group's total revenue for the period was approximately RMB 12,674,000, a decrease of about 26.6% from RMB 17,275,000 in the previous period, primarily due to government-imposed lockdowns[37]. - Sales costs for the period were approximately RMB 6,285,000, a decrease of about 20.2% from RMB 7,880,000, attributed to reduced revenue across all business segments[37]. Strategic Initiatives - The board believes that the funeral service business remains stable due to its concentration in densely populated cities in China, while the global biotechnology industry is experiencing rapid growth driven by increasing demand for healthcare services[42]. - The group has initiated a diversification strategy to actively engage in the cell industry, including investments in cell culture media research and development[42]. - The group plans to continue developing its funeral business while exploring opportunities in the cell industry through investments, mergers, and acquisitions to optimize its business structure and create new profit growth points[44]. - The group maintains a prudent financial management strategy and aims to leverage its market advantages to enhance cooperation with foreign biotechnology companies[42]. Corporate Governance - As of March 31, 2020, Hong Kong Gaoqi holds 220,475,000 shares, representing 29.69% of the company's issued share capital[47]. - The company did not have any significant contracts that directors had a direct or indirect interest in during the reporting period[51]. - The company faced delays in publishing its audited financial results for the year ended December 31, 2019, due to travel restrictions related to COVID-19[59]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements and confirmed compliance with applicable accounting standards[57]. - The company did not engage in any purchase, sale, or redemption of its listed securities during the reporting period[56]. - No directors or major shareholders had interests in any competing businesses during the reporting period[55]. - The company did not disclose any rights for directors to purchase shares or debt securities during the reporting period[52]. - There were no known individuals with 5% or more voting rights at the company's shareholder meetings as of March 31, 2020[50]. - The company did not establish any management contracts for significant parts of its business during the reporting period[53]. - The company has not disclosed any new products, technologies, or market expansion strategies in the provided documents[46].

活出精彩 Live life to the Fullest Third Quarterly Report 2019 活出精彩 Live life to the Fullest 第三季度報告2019 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在主板上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等 公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其 ...

Financial Performance - For the six months ended June 30, 2019, the company reported total revenue of RMB 31,705,000, an increase of 0.62% compared to RMB 31,509,000 for the same period in 2018[7]. - The gross profit for the same period was RMB 16,047,000, representing a gross margin of 50.6%, compared to RMB 15,309,000 and a gross margin of 48.7% in 2018[7]. - The company incurred a loss of RMB 1,969,000 for the six months ended June 30, 2019, an improvement from a loss of RMB 2,577,000 in the prior year[9]. - Basic and diluted loss per share for the six months was RMB 0.03, compared to a loss of RMB 0.39 per share in the same period of 2018[9]. - The total comprehensive income for the period, after tax, was RMB 622,000, compared to RMB 3,406,000 in the previous year[9]. - The company reported a net profit before tax of RMB 201 thousand for the six months ended June 30, 2019, a significant recovery from a loss of RMB 2,504 thousand in the same period of 2018[62]. - The group recorded a profit attributable to owners of approximately RMB 242,000, compared to a loss of RMB 2,869,000 in the previous period, resulting in earnings per share of RMB 0.03 compared to a loss of RMB 0.39 per share previously[143]. Cash Flow and Liquidity - Cash and cash equivalents as of June 30, 2019, amounted to RMB 115,764,000, a decrease from RMB 205,272,000 at the end of 2018[12]. - The company reported a net cash outflow from operating activities of RMB (2,565) thousand for the six months ended June 30, 2019, compared to RMB (2,364) thousand for the same period in 2018[22]. - The net cash inflow from investing activities was RMB 14,146 thousand for the six months ended June 30, 2019, compared to a net outflow of RMB (437) thousand in 2018[22]. - The company experienced a net cash outflow from financing activities of RMB (355) thousand in the first half of 2019, an improvement from RMB (967) thousand in the same period of 2018[22]. - The total cash and cash equivalents increased by RMB 11,226 thousand to RMB 115,764 thousand as of June 30, 2019, compared to RMB 101,345 thousand at the end of June 2018[22]. - The group maintained a healthy financial position with cash and bank balances of approximately RMB 115,764,000 as of June 30, 2019, up from RMB 103,467,000 at the end of 2018[145]. Assets and Liabilities - The company's total assets less current liabilities stood at RMB 149,700,000, an increase from RMB 111,043,000 in the previous year[12]. - The company’s total liabilities as of June 30, 2019, were RMB (161,984) thousand, reflecting a significant increase from RMB (153,297) thousand in the previous year[18]. - The total assets of the company as of June 30, 2019, were RMB 255,074 thousand, up from RMB 227,661 thousand as of December 31, 2018, showing an increase of approximately 12.06%[59]. - The total liabilities increased to RMB 160,228 thousand as of June 30, 2019, from RMB 123,818 thousand at the end of 2018, marking a rise of about 29.43%[59]. - The company’s lease liabilities include both current and non-current portions, with current lease liabilities amounting to RMB 4,178,000 and non-current lease liabilities at RMB 38,249,000[47]. Business Strategy and Future Outlook - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming periods[6]. - The company is focused on expanding its services in the funeral and related sectors, as well as in the sale of burial plots and tombstones, which are key areas for future growth[24]. - The company has introduced a new business segment focused on stem cell and immune cell services, which is expected to be a major value driver[54]. - The company plans to continue its focus on the funeral business while actively developing the cell industry through various investment collaborations[157]. - The company aims to create value for shareholders by seeking new business opportunities and optimizing its business structure for sustainable growth[157]. Accounting and Financial Reporting - The board of directors confirmed that the financial information presented is accurate and complete, with no misleading elements[2]. - The adoption of Hong Kong Financial Reporting Standard 16 resulted in an increase of RMB 31,513 thousand in right-of-use assets and a total lease liability of RMB 40,363 thousand as of June 30, 2019[36]. - The financial impact of HKFRS 16 did not have a significant effect on the earnings per share for the period[38]. - The total equity decreased by RMB 11,648 thousand due to the adjustments made under HKFRS 16[36]. - The audit committee, composed of three independent non-executive directors, reviewed the financial statements for the six months ended June 30, 2019, and confirmed compliance with applicable accounting standards[188]. Revenue Breakdown - The revenue from funeral services was RMB 29,958 thousand, an increase from RMB 29,234 thousand in the previous year, reflecting a growth of about 2.48%[74]. - The revenue from stem cell and immune cell sales was RMB 301 thousand for the six months ended June 30, 2019, compared to no revenue in the same period of 2018[67]. - Revenue from the sale of burial plots and tombstones was RMB 175 thousand for the six months ended June 30, 2019, up from RMB 123 thousand in the same period of 2018, indicating a growth of approximately 42.24%[67]. - The group's revenue from the Chinese funeral services business increased by approximately 2.5% compared to the same period last year, reaching RMB 29,958,000, which accounts for 94.5% of total revenue[134]. - Revenue from the Taiwan market decreased by approximately 8.3%, totaling RMB 1,308,000, representing 4.1% of total revenue[139]. - Revenue from the Hong Kong market saw a significant decline of 63.2%, amounting to RMB 264,000, which is 0.8% of total revenue[139]. Cost Management - Employee costs, including director remuneration, rose to RMB 9,583,000 for the six months ended June 30, 2019, up from RMB 7,991,000 in 2018, reflecting a 20% increase[79]. - Sales costs decreased by approximately 3.3% to about RMB 15,658,000 from RMB 16,200,000, attributed to cost control measures in funeral services[142]. - Administrative expenses were approximately RMB 9,484,000, down about 15.8% from RMB 11,261,000, reflecting effective cost control measures[142]. Shareholder Information - As of June 30, 2019, Hong Kong Gaoqi holds 220,475,000 shares, representing approximately 29.69% of the company's issued share capital[160]. - The weighted average number of ordinary shares for the six months ended June 30, 2019, remained unchanged at 742,500,000 shares[91]. - The stock option plan allows for a maximum of 74,250,000 shares to be issued, equivalent to 10% of the total issued shares as of the mid-term report date[171]. - The total number of shares that may be issued under the stock option plan and any other plans shall not exceed 30% of the total issued shares at any time[173].

活出精彩 Live life to the Fulle GROUP LIMITED SINO-LIFE 中國生命集團有 限 公 司 於開曼群島註冊成立的有限公司 股份代號:8296 2019 第一李度報告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所的GEM證券上市規則（「GEM上市規則」）而刊 載，旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董 事（「董事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢 ...

活出精歌 Live life to Fulles SINO-LIFE GROUP LIMITED 中國 生 市 集 限 国 足 巨 信 Incorporated in the Cayman Islands with limited liability 於 関曼群島註冊成立的有限公司 Stock Code 股份代號 : 8296 2018 Annual Report 年報 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the ...